SanegeneBio

SanegeneBio (圣因生物) is a clinical-stage biotech company focused on innovative RNA interference (RNAi) therapeutics, founded in 2021 by founder-CEO Dr. Wang Weimin, with Qiming Venture Partners among its investors . Built on a proprietary RNAi drug development platform — including its LEAD™ extrahepatic delivery technology — the company has assembled a pipeline spanning autoimmune, cardiovascular, metabolic diseases and obesity, with several candidates already in clinical trials; per Qiming Venture Partners' portfolio updates, these include complement C3-targeting siRNA drug SGB-9768, which started Phase 2 trials in China in early 2025, and CFB-targeting SGB-3383, which completed first-patient dosing in a Phase 1 study at Peking University Third Hospital . The company's momentum is recent and tangible: it closed an over-$110 million Series B in late 2025 (with Qiming continuing to back it), and in early 2026 signed a global R&D collaboration and license deal with Genentech worth a $200 million upfront payment plus up to $1.5 billion in milestones, which Wang described as "another important milestone" for the platform .